Chronic Lymphocytic Leukemia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chronic Lymphocytic Leukemia stocks.

Chronic Lymphocytic Leukemia Stocks Recent News

Date Stock Title
Jul 1 TEVA Update: Market Chatter: Teva Pharmaceuticals Faces FTC Probe on Patent Listings
Jul 1 TEVA Correction: Top Midday Stories: Boeing to Acquire Spirit AeroSystems; Robinhood Acquires Pluto; FTC Probes Teva; BlackRock Acquires Preqin; SCOTUS Grants Trump Some Immunity
Jul 1 TEVA Teva focus of FTC investigation over inhaler patents
Jul 1 GMAB AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
Jul 1 LGND Lifecore Biomedical Announces Cooperation Agreement with 22NW
Jul 1 BIIB 10 clinical trials to watch in the second half of 2024
Jun 28 TEVA New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
Jun 28 GMAB AbbVie, Genmab blood cancer therapy endorsed in EU
Jun 28 BIIB Biogen, Eisai launch Alzheimer's drug Leqembi in China
Jun 28 BIIB Eisai and Biogen launch LEQEMBI for Alzheimer’s in China
Jun 28 GMAB Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
Jun 28 BIIB Eisai and Biogen launch Alzheimer's drug Leqembi in China
Jun 27 BIIB “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
Jun 27 GMAB Completion of Share Buy-back Program
Jun 27 GMAB FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
Jun 27 LGND Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
Jun 27 GMAB Genmab, AbbVie win FDA nod for relapsed follicular lymphoma therapy
Jun 26 GMAB EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Jun 26 BIIB FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
Jun 26 BIIB Pharma M&A: The top high value deals in 2023
Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Early on there are typically no symptoms. Later non-painful lymph nodes swelling, feeling tired, fever, or weight loss for no clear reason may occur. Enlargement of the spleen and anemia may also occur. It typically worsens gradually.Risk factors include having a family history of the disease. Exposure to Agent Orange and certain insecticides might also be a risk. CLL results in the buildup of B cell lymphocytes in the bone marrow, lymph nodes, and blood. These cells do not function well and crowd out healthy blood cells. CLL is divided into two main types: those with a mutated IGHV gene and those without. Diagnosis is typically based on blood tests finding high numbers of mature lymphocytes and smudge cells.Management of early disease is generally with watchful waiting. Infections should more readily be treated with antibiotics. In those with significant symptoms, chemotherapy or immunotherapy may be used. The medications fludarabine, cyclophosphamide, and rituximab are typically the initial treatment in those who are otherwise healthy.CLL affected about 904,000 people globally in 2015 and resulted in 60,700 deaths. The disease most commonly occurs in people over the age of 50. Males are affected more often than females. It is much less common in people from Asia. Five-year survival following diagnosis is approximately 83% in the United States. It represents less than 1% of deaths from cancer.

Browse All Tags